浙江大学学报(医学版)
浙江大學學報(醫學版)
절강대학학보(의학판)
JOURNAL OF ZHEJIANG UNIVERSITY MEDICAL SCIENCES
2014年
2期
180-186
,共7页
吴丽娟%靳昌忠%白石%梁勇%吴南屏
吳麗娟%靳昌忠%白石%樑勇%吳南屏
오려연%근창충%백석%량용%오남병
获得性免疫缺陷综合征/药物疗法%肝炎, 乙型/并发症%肝炎, 丙型/并发症%抗病毒药/治疗应用%抗逆转录病毒治疗,高效%重叠感染%丙氨酸转氨酶/血液%天冬氨酸氨基转移酶类/血液
穫得性免疫缺陷綜閤徵/藥物療法%肝炎, 乙型/併髮癥%肝炎, 丙型/併髮癥%抗病毒藥/治療應用%抗逆轉錄病毒治療,高效%重疊感染%丙氨痠轉氨酶/血液%天鼕氨痠氨基轉移酶類/血液
획득성면역결함종합정/약물요법%간염, 을형/병발증%간염, 병형/병발증%항병독약/치료응용%항역전록병독치료,고효%중첩감염%병안산전안매/혈액%천동안산안기전이매류/혈액
Acquired immunodeficiency syndrome/drug therapy%Hepatitis B/complications%Hepatitis C/complications%Antiviral agents/ therapeutic use%Antiretroviral therapy,highly active%Superinfection%Alanine transaminase/blood%Aspartate aminotransferases/blood
目的:观察获得性免疫缺陷综合征( AIDS )患儿合并乙型肝炎病毒( HBV)/丙型肝炎病毒( HCV )感染与否在接受1年高效抗逆转录酶病毒疗法( HAART)后肝功能的变化情况。方法:收集2011年3月至2012年3月河南省141例AIDS患儿HAART治疗1年前后临床资料,分为HIV+HBV+HCV组( n=78),HIV+HBV组( n=19),单纯HIV组( n=44)。治疗前后分别用逆转录PCR检测血浆HIV RNA载量,流式细胞术检测CD4+T细胞数,酶联免疫吸附试验检测HCV抗体和HBV表面抗原,全自动生化分析仪检测丙氨酸转氨酶( ALT)、天冬氨酸转氨酶(AST)和总胆红素(TB)水平。结果:HAART治疗1年后,90.34%(127/141)患儿HIV RNA载量下降到检测水平以下( t=2.61, P<0.01), CD4+T细胞数从(170.187±132.405)个/μl上升到(796.014±158.491)个/μl(t=3.17, P<0.01)。 HAART治疗后患儿的转氨酶均升高( t=2.02,均P<0.05),奈韦拉平治疗组的ALT和AST分别由治疗前(18.28±13.74) U/L和(24.23±8.09) U/L升高到(55.35±22.40)U/L和(69.97±26.72)U/L(t=3.80、4.11,均P<0.01),同时奈韦拉平治疗组的 ALT 和AST变化量亦明显高于依非韦伦治疗组(均P <0.01);使用奈韦拉平治疗的HIV+HBV+HCV合并感染患儿ALT和AST的变化量亦显著高于使用依非韦伦治疗患儿(均P<0.01)。结论:无论是否合并HBV/HCV感染,HAART均能有效抑制病毒复制,使CD4+T细胞计数上升,但同时会一定程度损伤肝细胞,尤见于合并感染者;正确选择用药方案,能够减少药物不良反应。
目的:觀察穫得性免疫缺陷綜閤徵( AIDS )患兒閤併乙型肝炎病毒( HBV)/丙型肝炎病毒( HCV )感染與否在接受1年高效抗逆轉錄酶病毒療法( HAART)後肝功能的變化情況。方法:收集2011年3月至2012年3月河南省141例AIDS患兒HAART治療1年前後臨床資料,分為HIV+HBV+HCV組( n=78),HIV+HBV組( n=19),單純HIV組( n=44)。治療前後分彆用逆轉錄PCR檢測血漿HIV RNA載量,流式細胞術檢測CD4+T細胞數,酶聯免疫吸附試驗檢測HCV抗體和HBV錶麵抗原,全自動生化分析儀檢測丙氨痠轉氨酶( ALT)、天鼕氨痠轉氨酶(AST)和總膽紅素(TB)水平。結果:HAART治療1年後,90.34%(127/141)患兒HIV RNA載量下降到檢測水平以下( t=2.61, P<0.01), CD4+T細胞數從(170.187±132.405)箇/μl上升到(796.014±158.491)箇/μl(t=3.17, P<0.01)。 HAART治療後患兒的轉氨酶均升高( t=2.02,均P<0.05),奈韋拉平治療組的ALT和AST分彆由治療前(18.28±13.74) U/L和(24.23±8.09) U/L升高到(55.35±22.40)U/L和(69.97±26.72)U/L(t=3.80、4.11,均P<0.01),同時奈韋拉平治療組的 ALT 和AST變化量亦明顯高于依非韋倫治療組(均P <0.01);使用奈韋拉平治療的HIV+HBV+HCV閤併感染患兒ALT和AST的變化量亦顯著高于使用依非韋倫治療患兒(均P<0.01)。結論:無論是否閤併HBV/HCV感染,HAART均能有效抑製病毒複製,使CD4+T細胞計數上升,但同時會一定程度損傷肝細胞,尤見于閤併感染者;正確選擇用藥方案,能夠減少藥物不良反應。
목적:관찰획득성면역결함종합정( AIDS )환인합병을형간염병독( HBV)/병형간염병독( HCV )감염여부재접수1년고효항역전록매병독요법( HAART)후간공능적변화정황。방법:수집2011년3월지2012년3월하남성141례AIDS환인HAART치료1년전후림상자료,분위HIV+HBV+HCV조( n=78),HIV+HBV조( n=19),단순HIV조( n=44)。치료전후분별용역전록PCR검측혈장HIV RNA재량,류식세포술검측CD4+T세포수,매련면역흡부시험검측HCV항체화HBV표면항원,전자동생화분석의검측병안산전안매( ALT)、천동안산전안매(AST)화총담홍소(TB)수평。결과:HAART치료1년후,90.34%(127/141)환인HIV RNA재량하강도검측수평이하( t=2.61, P<0.01), CD4+T세포수종(170.187±132.405)개/μl상승도(796.014±158.491)개/μl(t=3.17, P<0.01)。 HAART치료후환인적전안매균승고( t=2.02,균P<0.05),내위랍평치료조적ALT화AST분별유치료전(18.28±13.74) U/L화(24.23±8.09) U/L승고도(55.35±22.40)U/L화(69.97±26.72)U/L(t=3.80、4.11,균P<0.01),동시내위랍평치료조적 ALT 화AST변화량역명현고우의비위륜치료조(균P <0.01);사용내위랍평치료적HIV+HBV+HCV합병감염환인ALT화AST적변화량역현저고우사용의비위륜치료환인(균P<0.01)。결론:무론시부합병HBV/HCV감염,HAART균능유효억제병독복제,사CD4+T세포계수상승,단동시회일정정도손상간세포,우견우합병감염자;정학선택용약방안,능구감소약물불량반응。
Objective: To assess changes of liver function in HIV-positive children with/without HBV/HCV co-infection after 1 year of highly active antiretroviral therapy ( HARRT ) . Methods: Seventy-eight pediatric AIDS patients with HBV/HCV co-infection,19 pediatric AIDS patients with HBV co-infection and 44 pediatric AIDS patients without HBV/HCV co-infection who received HAART at least for 1 year were enrolled .HIV-1 viral load was quantitatively detected using a standardized reverse transcriptase-polymerase chain reaction assay , and blood cells were determined by three-color flow cytometry . Anti-HCV antibody and HBsAg was detected using an enzyme-linked immunosorbent technique , and ALT, AST and TBIL were detected by automatic biochemical analyzer .Results: After 1 year-HAART, the viral load was decreased to the lowest limit of detection in 90 .34% patients ( t=2 .61 , P<0 .01 ) , and CD4 +T cell counts were increased from 170 .187 ±132 .405/μl to 796 .014 ± 158 .491/μl ( t=3 .17 , P<0 .01 ) .The levels of ALT and AST were elevated ( t=2 .02 , P <0 .05 ) , while the ALT and AST levels in patients receiving nevirapine (NVP) based HAART increased from 18.28 ±13.74 U/L and 24.23 ±8.09 U/L to 55.35 ±22.40 U/L and 69.97 ±26.72 U/L, respectively(t=3.80,t=4.11;Ps<0 .01 ) .The increment of ALT and AST in NVP based HAART were significantly higher than that in the efavirenz based HAART (ALT:46.28 ±13.35 U/L vs 37.70 ±15.25 U/L and AST:19.53 ±7.23 U/L vs 1.25 ±0.21 U/L, respectively; t=4.53, t=5 .79;Ps<0 .01 ) , particularly in patients co-infected with HIV/HBV/HCV ( ALT:54 .32 ±22 .85 U/L vs 16 .89 ±14 .42 U/L and AST:41 .71 ±19 .26 U/L vs -3 .44 ±15.59 U/L, respectively; t=3.42, t=2.98, Ps<0.01).Conclusion: HARRT can repress HIV-1 replication effectively , but it also cause the damage of liver function , especially in patients with HBV and/or HCV co-infection.